Sabra Health Care REIT, Inc. SBRA · NASDAQ
$21.47 +2.14% (+$0.45)
Summary
58 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 39 USD is left as free cash.
- Revenue grew by 7.4% a year over the last 3 years.
- Analysts expect revenue to grow by 20% this fiscal year.
What to watch
- Out of every 100 USD of revenue, only 7.8 USD is left as net profit.
- Operating profit covers the interest on its debt only 1.6 times.
- It earns only 2.5 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 78.7 USD for 1 USD of yearly profit. Over the last five years it was 101.2 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 5.3% a year over 5 years. Over the last 3 years it grew by 7.4% a year. For the next fiscal year analysts expect revenue to grow by 20%.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 39 USD
- Sales and administration 46 USD
- Taxes and other 7.0 USD
- Net profit 7.8 USD
Net profit, industry median (REIT - Healthcare Facilities) 13 USD
Out of every 100 USD of revenue, 7.8 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 6.8 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, at risk- Yield
- 5.59%
- Paid out of profit
- 440%
You receive $1.20 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Neutral- Buy 11
- Hold 16
- Sell 2
Today's price within the analysts' price targets
The average target of $21.86 is 1.8% above today's price. 38% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Health Care, Resident Service, Ancillary Service 100%
By region
The company reports no revenue by region.
Health Care, Resident Service, Ancillary Service brings in 100% of revenue.
Segments in detail